Natalizumab
ATC L04AG03 · 10 markets · 26 records
AU 7 records · 5 strengths
- 300 mg/15 mLinjectionTYSABRI
- 300 mginjectionTYRUKO natalizumab 300 mg/15 mL concentrate for infusion vialTYSABRI natalizumab 300mg/15 mL concentrate for infusion vial
- 150 mg/1 mLinjectionTYSABRI
- 150 mginjectionTYSABRI natalizumab 150 mg/1 mL injection solution pre-filled syringe
Records without a stated strength · 1 TYRUKO、TYSABRI
GB 3 records · 2 strengths
- 300 mg/15 mLinjectionTyruko 300mg/15ml concentrate for solution for infusion vialsTysabri 300mg/15ml concentrate for solution for infusion vials
- 150 mg/1 mLinjectionTysabri 150mg/1ml solution for injection pre-filled syringes
ES 3 records · 3 strengths
- 300 mginjectionTYRUKO
- 150 mginjectionTYSABRI PRECARGADA
- 20 mginjectionTYSABRI
MX 3 records · 1 strengths
Records without a stated strength · 1 TYRUKO、TYSABRI、TYSABRI SC
EU 3 records · 1 strengths
EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.
Records without a stated strength · 1 Natalizumab Elan Pharma、TYRUKO、TYSABRI
US 2 records · 1 strengths
- 300 mg/15 mLinjectionTYRUKOTYSABRI
CA 2 records · 1 strengths
- 20 mg/1 mLliquidTYRUKOTYSABRI
SG 1 records · 1 strengths
- 300 mg/15 mLinjectionTysabri concentrate for solution for infusion 300mg
TW 1 records · 1 strengths
- 300 mginjectionTysabri concentrate for solution for infusion 300mg泰吉利濃縮靜脈輸注液 300 毫克
HK 1 records · 1 strengths
Records without a stated strength · 1 Tysabri concentrate for solution for infusion 300mg
| Strength / form / release | US | GB | CA | AU | SG | ES | MX | TW | HK | EU |
|---|---|---|---|---|---|---|---|---|---|---|
| 300 mg/15 mL injection | TYRUKO TYSABRI | Tyruko 300mg/15ml concentrate for solution for infusion vials Tysabri 300mg/15ml concentrate for solution for infusion vials | TYSABRI | Tysabri concentrate for solution for infusion 300mg | ||||||
| 300 mg injection | TYRUKO natalizumab 300 mg/15 mL concentrate for infusion vial TYSABRI natalizumab 300mg/15 mL concentrate for infusion vial | TYRUKO | Tysabri concentrate for solution for infusion 300mg 泰吉利濃縮靜脈輸注液 300 毫克 | |||||||
| 20 mg/1 mL liquid | TYRUKO TYSABRI | |||||||||
| 150 mg/1 mL injection | Tysabri 150mg/1ml solution for injection pre-filled syringes | TYSABRI | ||||||||
| 150 mg injection | TYSABRI natalizumab 150 mg/1 mL injection solution pre-filled syringe | TYSABRI PRECARGADA | ||||||||
| 20 mg injection | TYSABRI | |||||||||
unknown | TYRUKO TYSABRI | Tysabri concentrate for solution for infusion 300mg | Natalizumab Elan Pharma TYRUKO TYSABRI | |||||||
liquid | TYRUKO TYSABRI TYSABRI SC |
Scroll horizontally for more markets →
Each country column shows the locally registered trade names — not translations.
2 more strength/form rows are recorded only in CA · MX and are not shown in this table. Hay 2 filas de concentración/forma registradas solo en CA · MX que no se muestran en esta tabla. 另有 2 个规格/剂型仅在 CA · MX 有记录(未在本表显示)。 另有 2 個規格/劑型僅在 CA · MX 有記錄(未在本表顯示)。
“not disclosed” means the source does not publish the strength — it does not mean the product has none.
Hong Kong records are name/ingredient-level only: no strength, dosage form or registration status; on the register does not prove current supply.
Australia ARTG data has no registration-status column, so status is shown as unknown; being on the register does not mean currently marketed.
EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.
Discontinued, withdrawn or unverified-status products are hidden by default; Hong Kong and Australia records are shown as exceptions.